Status:
COMPLETED
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
Purpura, Schoenlein-Henoch
Eligibility:
All Genders
Up to 17 years
Phase:
NA
Brief Summary
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schönlein purpura.
Detailed Description
The investigators designed a single center, open-label, prospective study that routinely administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory parameters to explore ...
Eligibility Criteria
Inclusion
- age \<18 years old
- meet the EULAR/PRINTO/PRES for the diagnosis of HSP
- HIV negative;Negative for HBV and HCV.
Exclusion
- heart failure (cardiac function ≥ grade III NYHA)
- liver insufficiency (upper limit of normal range of transaminase \> 2 times)
- renal insufficiency (creatinine clearance ≤30ml/min)
- acute or severe infections such as bacteremia and sepsis
- malignant tumor
- high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month
- mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information
- Intestinal ischemia or perforated gastrointestinal bleeding requires surgery
- Inability to comply with IL-2 treatment regimen.
Key Trial Info
Start Date :
June 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT04387942
Start Date
June 14 2020
End Date
June 30 2022
Last Update
August 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sirui Yang
Changchun, Changchun/JiLin, China, 130021